{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-160031","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2023-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.604116+00:00","generated_at":"2026-06-14T07:40:41.777054+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zymeworks reports 41.3% cORR for zanidatamab in HER2-amplified BTC from Phase 2b trial","bullets":["cORR of 41.3% (95% CI: 30.4-52.8) in Cohort 1 (IHC 2+/3+) by independent central review.","Median duration of response 12.9 months; median progression-free survival 5.5 months.","48.5% of responders had ongoing responses at October 10, 2022 data cutoff.","Only 2.3% of patients discontinued treatment due to adverse events; no Grade 4 or treatment-related deaths.","Data presented at ASCO 2023 and concurrently published in The Lancet Oncology."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-160031","json":"https://secwatch.observer/filing/0001193125-23-160031.json","markdown":"https://secwatch.observer/filing/0001193125-23-160031.md","text":"https://secwatch.observer/filing/0001193125-23-160031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000119312523160031/0001193125-23-160031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000119312523160031/d504484d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:40:41.777054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}